Kris on Oncology

 
 
  • Treating Progression of EGFR-Mutant Lung Cancer   When it comes to progression in a patient with EGFR-mutant lung cancer, it's by no means one-size-fits-all. Dr Mark Kris discusses treatment options.
  • Targeting ROS1-Positive Lung Cancers   The approval of crizotinib stands to have an outsize impact for a small but significant population of patients with ROS1-positive lung cancer.
  • Recent Advances in Squamous Cell Lung Cancer   Squamous cell tumors represent 20% of all lung cancers. Dr Mark Kris discusses new approaches to the diagnosis and treatment of these tumors, including nivolumab and ramucirumab.
  • HER2 Dependency in Lung Cancers   What have we learned about treating HER2-mutant lung cancers? Dr Mark Kris explores this new topic in the field of thoracic oncology.
  • IMPRESS Trial: Navigating the Switch to Chemo From a TKI   Dr Mark Kris discusses the details of the IMPRESS trial, which assessed the effect of discontinuing gefitinib in patients with EGFR-mutant lung cancer who have developed resistance to the drug.
  • Recognizing the Dedicated Effort to Treat Emesis   Dr Mark Kris recognizes the achievements of the dedicated group of researchers who developed antiemetics, helping to overcome one of the most feared side effects of cancer treatment.
  • EGFR Mutant Lung Cancer: Lessons From ASPIRATION and IMPRESS   Dr Mark Kris discusses the switch from first- to second-line therapy for EGFR mutant lung cancers in light of two studies presented at the most recent ESMO meeting.
  • The Case for Neoadjuvant Therapy in Lung Cancer   Dr Mark Kris discusses the benefits of neoadjuvant therapy for patients with locally advanced lung cancers, from treating micrometastases to assessing response to therapy.
  • Four Years After NLST, Lung Screening Uptake 'Way Too Slow'   Dr Mark Kris reviews recent developments in lung cancer screening and calls on the oncology community to recommend screening to all eligible candidates.
  • The Value of Multiplex Genotyping for Lung Cancer   Dr Mark Kris discusses the development of the Lung Cancer Mutation Consortium, a group of lung cancer specialists who sought to prove the value of multiplex genotyping.
  • Genotyping in Lung Cancer: New Opportunities, New Challenges   Dr Ronald Wharton reviews images from a patient with a bioprosthetic aortic valve and a mitral-valve ring annuloplasty.
  • Detecting and Treating ALK-Positive Lung Cancers   Dr. Mark Kris discusses how to reliably detect ALK-positive lung adenocarcinomas and how to use new therapies -- in particular the drug ceritinib -- to treat these patients.
  • New Agents Topple Resistance in NSCLC   Dr. Mark Kris reports on new agents that overcome acquired resistance to EGFR TKIs in patients with NSCLC who have a T790 mutation, and recommends rebiopsying patients to identify who would benefit.
  • An Agent Not Well MET in Lung Cancer   Dr. Mark Kris reports on 2 studies on MET inhibition in NSCLC that underscore the importance of defining the patient population who would benefit from a targeted therapy.
  • Stage IIIA NSCLC: Advantages of Neoadjuvant Therapy   Dr. Mark Kris discusses the risks and benefits of using neoadjuvant therapy vs chemoradiation preoperatively for patients with stage IIIA lung cancer.
  • EGFR Inhibitor Poised to Change Practice in NSCLC   Drs. Mark Kris and Luis Paz-Ares highlight lung cancer presentations from ASCO 2014, including a promising agent in squamous cell and a new EGFR-TKI that overcomes resistance and may change practice.
  • A Tribute to Three 'Dads'   Dr. Mark Kris credits his father, who worked in a chemotherapy laboratory, and two thoracic surgeons as role models and mentors in his journey to become a medical oncologist.
  • Taking Lung Cancer Treatment to the 'Next Level'   Dr. Mark Kris highlights exciting studies in lung cancer to be presented at ASCO 2014: new drugs to watch, surrogate endpoints, and a potentially practice-changing abstract on brain metastases.
  • Patient-Preferred Therapy in ALK+ Lung Cancer   Dr. Mark Kris underscores the advantages of crizotinib and other ALK-targeted therapies for ALK+ lung cancer and looks askance at recent data on toxicity levels and cost-effectiveness of testing.
  • 'The Time Is Now' for Lung Cancer Screening   Even as an advisory panel recommends against national Medicare coverage of lung cancer screening, Dr. Mark Kris stresses the number of lives saved by this well-evidenced means of early detection.